• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Rheumatology

Show Search
Hide Search
  • About Us
    • Our History
    • Our Faculty
    • Rheumatology Fellowship
    • Administrative Core
    • Contact Us
    • eNews Signup
  • Make an Appointment
    • Clinic Information
    • Specialty Clinics
  • Our Research
    • Current Research Studies
    • Andrade Lab
    • Antiochos Lab
    • Casciola-Rosen Lab
    • Darrah Lab
    • Konig Lab
    • RDRCC
    • Bayview Immunomics Core (BIC)
  • Charitable Giving
    • Dr. John Welton Fellowship in Rheumatology
    • Dr. Ira T. Fine Discovery Fund
    • Dr. Nadia D. Morgan Memorial Fund
  • News
    • LEAP Magazine
  • Education
    • Advances in the Diagnosis and Treatment of the Rheumatic Diseases Course
    • RheumTV – Patient Education Video Library
Home / News / Research / Multiple Autoimmune Responses in Scleroderma May Protect Against Cancer

Multiple Autoimmune Responses in Scleroderma May Protect Against Cancer

October 30, 2019 By Ashley Curran

Summary

These investigators are studying why cancer is often detected around the time that scleroderma is diagnosed. Building on their previous work showing that cancer may trigger the autoimmune response in scleroderma, this team now provides data showing that while some autoantibodies are associated with increased cancer incidence (e.g., anti-RNA pol III antibodies), combinations of these antibodies with others (e.g., anti-RNA pol III + anti-RPA194) may protect against cancer.

Why was this study done?

Previously, these researchers found that 15% of scleroderma patients with autoantibodies against RNA pol III have a cancer diagnosed around the same time that scleroderma develops. Those cancers often have mutations in the POLR3A gene, which encodes the RNA pol III protein, suggesting that mutation of the gene initiates an immune response against the mutant protein. This immune response subsequently broadens to include normal versions of the protein and suggests a scenario in which cancer triggers the development of autoimmunity. In the current study, the authors investigated whether there was something unique about the 85% of patients with anti-RNA pol III antibodies who do not have a cancer diagnosis.

How was this study done?

The Johns Hopkins Scleroderma Center followed a group of 168 patients with anti-RNA pol III antibodies for five years and tracked the development of cancer in these patients. After this period, they compared the antibodies present in those patients with and without a detectable cancer.

What were the major findings?

The authors focused on people with scleroderma who had antibodies to RNA pol III and found a new antibody that was enriched in people who did not develop cancer. They found that 18.2% of the patients without cancer also made antibodies against the large subunit of RNA polymerase I (called anti-RPA194) – compared to only 3.8% of those with cancer.

What is the impact of the work?

These new data suggest that cancers present at levels too low to be detected clinically may still trigger an immune response against the tumor. In those patients who mount multiple different immune responses (e.g., antibodies against both RNA pol I and RNA pol III), there may be a greater chance that the cancer will be eliminated by the immune system. A byproduct of the immune response against cancer may be the development of scleroderma in some people. Clinically important questions raised by these studies include whether autoantibodies may be useful biomarkers to assess cancer risk for newly diagnosed scleroderma patients, whether “cancer-protective” antibodies may be used for cancer therapy, and whether treating an underlying cancer will also effectively treat scleroderma.

This research supported by:

  • National Institutes of Health. Grant Numbers: 1R01 AR073208, K23 AR061439, P30‐AR070254, R01 GM12104
  • Scleroderma Research Foundation
  • Donald B. and Dorothy L. Stabler Foundation

Publication Information

Ami A. Shah, Antony Rosen, and Livia Casciola-Rosen (Rheumatology)
Marikki Laiho (Radiation Oncology)

Others in the Rheumatology Team: Adrianne Woods (data management and quality control), Margaret Sampedro (acquisition of biologic samples), and Drs. Laura Gutierrez-Alamillo and Qingyuan Yang (expert technical assistance).

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Filed Under: Research Tagged With: Scleroderma

Ashley Curran

Ashley Curran is a PhD candidate in the Johns Hopkins University Division of Rheumatology studying the mechanisms by which autoimmune responses develop in rheumatoid arthritis.

Use of this Site

All information contained within the Johns Hopkins Division of Rheumatology website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Rheumatology News

  • News
  • Promotions

Recent News

LEAP Winter 2025: Fighting Fire with Fire

February 27, 2025

LEAP Winter 2024: At the Cusp of Breakthroughs

February 23, 2024

LEAP – Winter 2023: Big Data, Individualized Care

February 23, 2024

RheumTV Logo

Rheum.TV is an educational platform created to help patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit RheumTV

Footer

Rheumatology Specialty Care Centers

  • Johns Hopkins Arthritis Center
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect with Us

  • Facebook
  • Twitter
  • YouTube
U.S. News and World Report Rankings Badge

Johns Hopkins Medicine

© 2025 Johns Hopkins Rheumatology - Patient Privacy